Aurinia Pharmaceuticals Inc.'s SEC filings document the formal reporting record for a Canada-incorporated biopharmaceutical company commercializing LUPKYNIS and developing autoimmune-disease therapies. 8-K filings furnish operating and financial results, product revenue, license, collaboration and royalty revenue, research and development spending, guidance-related exhibits and other material-event disclosures.
The filings also cover proxy governance, executive appointments and compensatory arrangements, shareholder voting matters, capital-structure disclosures, share repurchase activity and material agreements. Recent transaction records include completed acquisition activity, tender-offer and merger mechanics, and contingent value right terms.
Aurinia Pharmaceuticals (AUPH) reported stronger Q3 2025 results, led by continued LUPKYNIS growth and lower operating costs. Total revenue was $73.5 million, up from $67.8 million a year ago, with net product sales of $70.6 million. Net income rose to $31.6 million from $14.4 million as SG&A spending declined following 2024 restructuring actions. Gross margin was 89% for the quarter.
Year to date, revenue reached $205.9 million and net income was $76.4 million. Operating cash flow for the nine months was $90.0 million. Cash, cash equivalents, restricted cash and investments were $351.8 million as of September 30, 2025. The company repurchased 12.2 million common shares year to date under its authorized program. Common shares outstanding were 131,840,559 as of November 3, 2025.
This Amendment No. 16 to the Schedule 13D reports the holdings and recent transactions by ILJIN-related reporting persons in Aurinia Pharmaceuticals Inc.'s common shares. Chin Kyu Huh beneficially owns 6,535,141 shares, equal to 5.0% of the outstanding class, and certain ILJIN entities report shared voting and dispositive power over 5,411,533 shares (4.1%). The filing states small purchases by family members and material secondary-market sales by ILJIN SNT and a family member, with per-share prices disclosed.
The filing also states the Reporting Persons may be deemed a group for Section 13(d)(3) purposes while disclaiming certain beneficial ownerships among family members and entities. All percentage calculations are based on 131,629,546 shares outstanding as reported by the issuer.
Aurinia Pharmaceuticals Inc. (AUPH) – Form 4 insider buying
Director Kevin Tang, through Tang Capital Partners LP and Tang Capital Partners International LP, purchased a total of 1,300,000 common shares in three open-market transactions dated 1-5 Aug 2025 (transaction code P). Weighted-average purchase prices were:
- 1,000,000 sh @ $10.12 (range $9.23-$10.50)
- 100,000 sh @ $11.34 (range $11.11-$11.48)
- 200,000 sh @ $11.68 (range $11.49-$11.80)